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INTRODUCTION
Designing perinatal trials is a continuing challenge.
In the process, the choice of primary outcome is
one of the critical decisions and one that will deter-
mine the necessary trial size and ultimately the
success or failure. The primary outcome should be
directly causally relevant to the intervention under
study and the difference sought must be clinically
relevant. Alongside the test of efﬁcacy, there is also
a need to ensure that a treatment is safe. Few trials
are now designed without a measure of develop-
mental outcome at 18–24 months as a primary or
coprimary outcome.1 This is a complex outcome,
being a composite usually of death and four to ﬁve
domains of developmental impairment, based on
value judgments as to severity of impairment in the
areas of motor, cognitive, hearing and visual func-
tions, and sometimes communication. I would like
to address a range of issues with the use of this as a
composite outcome and the extent to which we
should rely on it to show beneﬁt when we are
assessing research based evidence about
interventions.
This paper discusses the relevance of 2-year out-
comes in several trials and develops some ideas as
to how we might consider 2-year outcomes, in
terms of their interpretation and in the implemen-
tation of trial data into practice.
ROBUSTNESS OF 2-YEAR OUTCOMES
Recently I reviewed the challenges in measuring
2 year outcomes in research practice.1 They pose real
issues in quality control, diagnostic accuracy and
interpretation of the measures themselves in practice.
Their predictive value for an individual is relatively
poor, except for the most severe impairments.2 Most
studies use a combined severe and moderate outcome
classiﬁcation similar to that published by British
Association of Perinatal Medicine.3 We can improve
the predictive accuracy by reducing noise in the
measure from variation in assessment technique or
by statistically correcting for demographic factors,4
but the latter is difﬁcult to justify within the conﬁnes
of a properly designed clinical trial, where such
factors should segregate equally between groups. IQ
and educational measures at school age may provide
better targets for outcome, in terms of being more
reliable, but run the risk of large losses to follow-up
and extending the duration of each study.
RELEVANCE OF 2-YEAR OUTCOMES
Although we often cite ‘2-year outcome’ as the
‘primary’ outcome we use a composite outcome
that includes death and a range of impairments
summated as ‘disability’ (or survival without dis-
ability). The argument runs that we have to
account for mortality in a high mortality setting,
such as a very preterm population, because an
effect on death might mask the effect of the inter-
vention on other outcomes, if the risk of death is
different in the two groups. As a byproduct of
including deaths, the prevalence of the primary
outcome is increased, and thereby the power of the
study, rendering the calculated trial size smaller
than it might otherwise need to be. Although it is,
at ﬁrst look, a useful end point for a trial, we do
see many trials that show little effect on this com-
bined outcome. This leads to the questions—was
this composite outcome correctly chosen in the
ﬁrst place, are the effects of the treatment so
diluted by other events causing disability that no
effect was seen, or is the treatment ineffective?
There are two aspects to this that bear some
thought.
First, such a composite outcome may be consid-
ered useful if the effects on death and on disability
are continuous in their relation to causation in this
context (and therefore act in the same direction).
The two components are clearly hierarchical, and
in a trial in a population where there is high mor-
tality and high rates of morbidity from the condi-
tion under treatment, it is difﬁcult to evaluate one
without the other. This is the advantage of such a
composite outcome: allowing the investigator to
get out of the challenge of deﬁning a single end
point when the risk studied by the intervention
affects the chances of survival and of morbidity
(competing risks). Occasionally some interventions
may act in different directions for different compo-
nents: there may be an increase in deaths but a
decrease in morbidity, for example. How we cope
with this in analysis and in drawing conclusions is
challenging and becomes a matter of judgment.
One of the ﬁrst steps is to ensure that the compo-
nents of the composite are reported alongside the
primary outcome, facilitating interpretation and
transparency. These component outcomes are then
compared between groups after, for example,
removing deaths, and after statistical adjustments
for the multiple comparisons that are undertaken,
something that is often not done. Assessing effects
on single components of the composite has consid-
erably less power than the composite and trials are
rarely powered on such an analysis. Hence effect
size has to be large to show an effect on a single
component.
We currently face such a dilemma when evaluat-
ing the results of the ﬁve trials of oxygen saturation
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targeting. It seems clear from the ﬁrst published meta-analysis5
that mortality is increased in the group with the lower targeting
range (relative risk: 1.41 (95% CI 1.14 to 1.74)) but the rate of
retinopathy may be increased in the higher targeted group (RR:
0.74 (0.59 to 0.92)), leading to increased potential visual
impairment. As it is, for the purposes of the prospective
meta-analysis the chosen end point is the composite of death
and abnormal neurodevelopment6; visual impairment is likely
to be a tiny proportion of the latter (and much due to central
visual impairment rather than retinal problems), but clearly
there is a major tension between directly relevant intermediate
outcomes so far. The interpretation of the 2-year outcomes will
be difﬁcult.
Second, using this speciﬁc composite 2-year outcome we need
to have a strong view that death and disability are on a direct
causal pathway from the intervention under test. Although it is
true that if a baby has died they cannot develop impairment,
often cited as an argument for using combined outcomes,
failing to ensure both are on a direct causal pathway will run
the risk of missing an important treatment effect. Furthermore
to use a more general composite outcome reduces the risk of
ﬁnding any effect, as other inﬂuences that determine the pro-
portion of children who die or have developmental, neuro-
logical or sensory impairment may overwhelm or dilute a small
effect from the treatment. Ideally, among those children with
death or disability we need to determine the proportion for
whom the outcome is directly the result of the target of our
intervention (true positive) or due to other causes (false posi-
tives). In any trial the higher the rate of ‘false positives’, the
greater the likelihood of a null result.7 8 Thus, among the
myriad events that led to brain injury, the proportion that were
directly related to the trial intervention (and what were due to
other events), becomes an important question, as it is for deaths
and sensory impairments.
In the example of a recent large trial of magnesium sulfate
for neuroprotection9 the chosen end point was death or moder-
ate/severe cerebral palsy rather than a more general impaired
outcome; this was chosen because it was thought to be related
better to the concept of neuroprotection. This composite was
not signiﬁcantly different between groups (RR: 0.97 (0.77 to
1.23); p=0.80). Death was considered important because of the
results of a smaller earlier trial that claimed to show signiﬁcantly
increased mortality risk, although there appeared to be no
direct causative pathway.10 In this trial of antenatal magnesium
sulfate, there was a non-signiﬁcant increase in deaths in the mag-
nesium group (RR: 1.12 (0.85 to 1.47)) but a signiﬁcant reduc-
tion in the proportion with cerebral palsy (RR: 0.55 (0.32 to
0.99)). Further secondary analysis revealed that many of the
deaths were ascribed to the presence of a congenital anomaly
(ie, false positives), removal of which reduced the risk to 1.03.
Hence it seems reasonable to conclude that magnesium sulfate
infused during preterm labour reduces the risk of cerebral palsy
without increasing mortality appreciably. Within the same trial
they also carried out developmental testing but found no differ-
ence in proportions of children meeting conventional cut-offs
for impairment (<70 or <85). Twenty children in the magne-
sium sulfate group and 24 children in the placebo group did not
have Bayley results for reasons that are not stated. Previous
experience has shown that those not followed may be the ones
with greatest impairment, thus interpreting these ﬁndings is
challenging—particularly if there was an excess of children with
cerebral palsy who did not receive developmental testing, which
was carried out in that study at a second assessment visit. Had
the authors chosen an even more complex end point—death or
multicomponent disability—results may have driven very differ-
ent conclusions. The ﬁndings of this trial are reinforced by con-
ﬁrmation in a systematic review.11
One way to get around the high rate of false positives is to
target a high-risk group in the study—to individualise trial
entry. For example the two largest trials of high frequency oscil-
lation are subtly different though often combined in
meta-analysis. The UKOscillation Study accepted all comers and
started as soon after birth as possible. This was irrespective of
the severity of lung disease; no effects on neonatal or on long-
term outcomes to 2 years was found.12 In the second trial13 trial
entry was delayed until it was clear that surfactant had been
ineffective; high frequency ventilation was effective at reducing
bronchopulmonary dysplasia (BPD) in this study. Much has
been made of the conﬂicting results between the two trials but
this fundamental difference is rarely acknowledged, making it
difﬁcult to combine the two studies.
2-YEAR OUTCOME AS AN APPROPRIATE TARGET
Finally we might consider whether 2-year outcomes are in fact
the most appropriate efﬁcacy outcome. Many interventions in
the neonatal period are targeted on short-term beneﬁt and, as
such, their combined beneﬁt may in time lead to improved neu-
rodevelopmental outcomes. However using neurodevelopmental
outcomes as primary outcomes for single agent trials, as indi-
cated above, may hide signiﬁcant effects if the neonatal beneﬁts
are not weighed in the assessment. For example, most would
agree that indometacin is a useful treatment for patent arterial
ducts. Prophylactic indometacin as studied in the Trial of
Indomethacin Prophylaxis in Preterms (TIPP) trial is associated
with reduced need for rescue treatment with further drug or
surgery and, as a by-product, with a smaller proportion of
babies with a large intraventricular haemorrhage—overall 12%
of the population.14 There was, however, no beneﬁt in reducing
the proportion with death or disability at 18 months, which was
present in 46.5% of the population. This does not mean that
these neonatal beneﬁts should be ignored, simply that other
factors leading to death or impairment may overwhelm the
signal from a reduction in a less prevalent risk factor. Thus the
data would seem to show that prophylactic indomethacin to
reduce problems associated with patent arterial ducts is a safe
therapy. Indeed the investigators recently posited the rhetorical
question: “why would a sane clinician not prescribe prophylac-
tic indomethacin?”15
In several trials of interventions in the immediate or early
neonatal period currently being proposed, the primary outcome
is death or impairment at 2 years. Is this sensible? Would we
eschew the use of the intervention on the premise it didn’t
improve 2-year outcomes, despite clear neonatal beneﬁts? In
this we might use as examples two current interventions where
trials are being planned.
First, trials of immediate or delayed cord clamping: in these
there is a drive to show that delaying cord clamping improves
2-year outcomes, if successful this would settle any lingering
concerns about the practice. Presumably this effect is via a route
whereby deaths are avoided because of improved early condi-
tion, brain outcomes are improved because of less low blood
pressure (or the interventions used to correct it), etc. Many
other factors compete for these casual pathways and I would
suggest that the route from intervention to effect on 2-year out-
comes is so complex that it is impossible to disentangle the
effect of one intervention from other causes of what are false
positive outcomes without a huge trial in which the competing
risks are well balanced. Second, trials of non-steroidal
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interventions for BPD may use 2-year outcomes on the basis
that BPD is related to developmental outcome. The effect of the
intervention in reducing BPD is important and clear, whereas
the effect on neurodevelopment is likely to be diluted with so
many other inﬂuences (false positives) that this effect is lost.
Should these trials not be designed primarily on short-term
end points that are directly related to delaying cord clamping or
to respiratory outcomes, respectively, and determine whether
these factors, intermediate in the potential causal pathways,
have been affected? Subsequently longer-term outcomes might
then be considered, but I would view the 2-year outcomes as
primarily a safety assessment.
CONCLUSION
Thus in conclusion, we have invested in the use of 2-year neuro-
developmental outcomes as markers of our care and as results
to use in research. We need to be aware of the nature and
dangers of using such a complex composite outcome in research
and to be prepared to use it as evidence of safety in situations
where the neonatal signal from an intervention is likely to be
overwhelmed by other inﬂuences that determine outcome. We
should tailor the outcome to the causal pathway we are testing
in order to reduce to a minimum the false positive outcomes to
maximise our ability to detect effects of treatments. This may
only mean using certain components of the impairment classiﬁ-
cation. Finally we should not be afraid to regard 2-year out-
comes as proof of safety rather than efﬁcacy, and therefore be
reassured in using the treatment. Multiple interventions will
combine to produce incremental beneﬁt in outcomes, such as
those seen in the EPICure studies,16 but individual interventions
may produce beneﬁts that are undetectable in terms of 2-year
outcomes. This does not mean they are worthless.
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